Nymox Pharmaceutical Corporation income statement NYMXF

Annual Quarterly

It recorded a net loss of $4.5 million. Across the 4 fiscal years shown, revenue shrank from $224,000 in fiscal 2017 to $5,000 in fiscal 2020, about 71.8% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017
Revenue	—	0	0	0 -100.0%	0 -95.7%	0 -61.2%	0 +33.5%	0
Cost of revenue	—	0	0	0 -100.0%	0 -93.1%	0 -58.0%	0 -7.4%	0
Gross profit	—	0	0	0 -100.0%	0 -98.3%	0 -64.0%	0 +114.7%	0
Research and development	3 -17.9%	4 +5.9%	4 -43.3%	7 -18.0%	8 +10.1%	7 +10.5%	7 -15.2%	8
Selling, general and administrative	1 -77.0%	4 +51.3%	3 -50.8%	6 +62.3%	4 -40.0%	6 +45.6%	4 -24.0%	5
Operating income	-4 +48.7%	-8 -25.5%	-7 +46.8%	-13 -6.7%	-12 +12.0%	-13 -25.2%	-11 +19.6%	-13
Pretax income	-4 +49.2%	-9 -34.5%	-7 +47.5%	-13 -6.8%	-12 -7101.2%	-0 +98.5%	-11 +21.1%	-13
Income tax	0	0	—	—	0	—	—	—
Net income	-4 +49.2%	-9 -34.5%	-7 +47.5%	-13 -6.8%	-12 +10.8%	-13 -24.2%	-11 +21.1%	-13
Basic EPS	-0.05 +50.0%	-0.10 -42.9%	-0.07 +53.3%	-0.15	—	—	—	—
Weighted average shares, basic	94 +2.2%	92 +2.6%	89 +9.0%	82 +11.0%	74 +7.2%	69 +13.9%	60 +14.8%	53
Other measures
Interest coverage	-18.95x	-143.97x	-237.57x	—	—	-740.28x	-591.17x	—
Margins
Gross margin	—	—	—	—	20.00%	50.00%	53.85%	33.48%
Operating margin	—	—	—	—	-234,400.00%	-11,487.07%	-3,558.86%	-5,908.48%
Pretax margin	—	—	—	—	-234,760.00%	-140.52%	-3,543.14%	-5,995.09%
Profit margin	—	—	—	—	-234,760.00%	-11,346.55%	-3,543.14%	-5,995.09%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as: NYMXF (OTC)
Fiscal year ends: December 31
Headquarters: Quebec Canada, Quebec, Canada
SEC filer status: Accelerated filer
SEC CIK: 1018735

Other In Vitro & In Vivo Diagnostic Substances companies

All 21 In Vitro & In Vivo Diagnostic Substances companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.